Anti-CEA (T84.66) h(CD28-CD3ζ) CAR, pSBCAR1 vector

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Details

Target
CEA

Targeting Cell Type
T cell

Targeting Diseases
Colon Cancer

Generation
Second

Vector Name
pSBCAR1

Vector Length
~6kb

Vector Type
Sleeping Beauty (SB) transposon

Receptor Construction
scFv-CD28-CD3ζ

Discription of Signaling Cassetes
CD28
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide costimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

Customize Your CAR Products

Published Data

Complete CAR data FCM

Fig.1 Anti-CEA CAR T cells specifically target CEA-positive mouse adenocarcinoma cells in vitro.

CAR Construction : T84.66 scFv-28ζ

Fig.1 Anti-CEA CAR T cells specifically target CEA-positive mouse adenocarcinoma cells in vitro.

Transduction efficiency was evaluated by flow cytometry for CD19t expression on transduced T cells.

Cha, S. E., Kujawski, M., J. Yazaki, P., Brown, C., & Shively, J. E. (2021). Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. Oncoimmunology, 10(1), 1899469.

Complete CAR data IHC

Fig.2 CEA expression on s.c. MC38/CEA tumors in CEATg mice.

CAR Construction : T84.66 scFv-28ζ

Fig.2 CEA expression on s.c. MC38/CEA tumors in CEATg mice.

The tumor-bearing mice were treated at day 12 after tumor implantation with a combination of CY, mock transduced T cells, and/or anti-CEA CAR T cells.

Complete CAR data FuncS

Fig.3 Therapeutic efficacy of cyclophosphamide plus repeated anti-CEA CAR T cell therapy on s.c. MC38/CEA tumor in CEATg mice.

CAR Construction : T84.66 scFv-28ζ

Fig.3 Therapeutic efficacy of cyclophosphamide plus repeated anti-CEA CAR T cell therapy on s.c. MC38/CEA tumor in CEATg mice.

Tumor volume for each group was measured until they reached 1500 mm3. Anti-CEA CAR T cell therapy was statistically
significant up to 23 days post tumor implantation (p < .001).

Complete CAR data Cyt

Fig.4 Effects of anti-CEA-IL2 immunocytokine (ICK) on anti-CEA CAR T cell activity in vitro.

CAR Construction : T84.66 scFv-28ζ

Fig.4 Effects of anti-CEA-IL2 immunocytokine (ICK) on anti-CEA CAR T cell activity in vitro.

Quantification of cell cytotoxicity of MC38/CEA/GFP by mock or anti-CEA CAR T cells following 24 hour co-culture with ICK (12 ng/mL) at an increasing effector:target (E:T) ratios.

More Published Data More Published Data

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Anti-CEA (T84.66) h(CD28-CD3ζ) CAR, pSBCAR1 (CAR-SB-LX0159)

Specific Inquiry

Details

Target

Customize Your CAR Products

Customer Reviews and Q&As

Related Products

CAR Cell Products

CAR Vector Products

CAR Viral Particles